In this article, we will look at the 10 Best New Stocks to Buy Other Than SpaceX.
Newly listed stocks have been getting more attention as investors look for companies that are still early in their public-market life cycle. Renaissance Capital describes its IPO-focused strategy as a way to access the “largest, most liquid US-listed newly public company stocks.” The firm also highlights the idea of getting exposure “prior to their inclusion in core U.S. equity portfolios,” while telling investors to get in early on newly-traded companies.
First Trust makes a similar case, saying its strategy provides “timely and systematic exposure to newly listed companies.” The firm also ties IPOs and spin-offs to the “growth and innovativeness of the U.S. economy,” which fits the broader reason investors follow newly public companies. Many of these businesses come to market with exposure to themes such as artificial intelligence, healthcare innovation, financial technology, industrial automation, and consumer platforms.
At the same time, Fidelity notes that “There are risks associated with investing in a public offering,” including “unproven management.” The best new stocks are not simply the most hyped IPOs, but companies where the public-market story is becoming more credible after listing. With that in mind, let’s take a look at the 10 Best New Stocks to Buy Other Than SpaceX.
Photo by osamu nakazawa on Unsplash
Our Methodology
We used the Finviz screener to identify stocks that were listed within the last 12 months, excluding SpaceX. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Medline Inc. (NASDAQ:MDLN)
On June 12, 2026, William Blair analyst Brandon Vazquez said Medline Inc. (NASDAQ:MDLN) shares were lower after news of a fire at a distribution center in Tracy, California. Vazquez noted that the 1M square-foot facility represents 4% of Medline’s warehouse space in the U.S. and 3% globally. William Blair expects Medline to spend to ensure customer orders are fulfilled, which could pressure margins in the short term. Still, Vazquez expects the stock impact to be “manageable over the medium term,” citing Medline’s scale and ability to continue fulfilling customer orders. William Blair kept an Outperform rating on Medline.
Also on June 12, Leerink analyst Michael Cherny noted that a fire broke out the previous afternoon at Medline’s Tracy, CA, 1 million sq. ft. distribution facility, completely engulfing the building. No injuries were reported, and local authorities were still assessing the situation. Cherny said the facility had at least been taken offline, meaning Medline was evaluating contingency plans to maintain customer order fulfillment. Leerink expects some short-term financial impact and possible disruption in product availability and fill rates, even if redundancy plans help mitigate the issue. Longer term, Cherny said the fire does not change Medline’s opportunity, and Leerink maintained an Outperform rating.
Earlier, ABC7 News reported that a massive fire destroyed Medline’s 1 million-square-foot medical supply distribution center in Tracy, California, citing Tracy Police Department spokesperson Kaylin Heefner. Management noted that everyone in the facility was safe and accounted for, with no injuries reported so far. The warehouse fire started around 1 p.m. Thursday and was still burning Friday morning.
Medline Inc. (NASDAQ:MDLN) manufactures med-surg products for hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and internationally.
9. Cerebras Systems Inc. (NASDAQ:CBRS)
On June 24, 2026, Morgan Stanley raised its price target on Cerebras Systems Inc. (NASDAQ:CBRS) to $273 from $250 and kept an Overweight rating following what the firm called “a strong first quarter out of the gates.” Morgan Stanley said the IPO happened recently enough that it expected solid results with no surprises and presumed some IPO conservatism in forecasts. The firm added that better gross margin guidance “certainly indicates a conservative guidance mindset.”
Also on June 24, UBS raised its price target on Cerebras Systems to $320 from $300 and kept a Buy rating. UBS viewed Cerebras’s first post-IPO earnings call positively after raising guidance and confirmation of an Amazon (AMZN) agreement. The firm also pointed to broader customer diversification and accelerating demand for specialized infrastructure as factors that could support strong growth through the decade, with supply constraints likely becoming the main limitation rather than demand.
Wedbush also raised its price target on Cerebras Systems to $280 from $270 and kept an Outperform rating. Wedbush said Cerebras reported results ahead of initial expectations with no major surprises, while ongoing engagements with large customers support a constructive outlook.
Cerebras Systems Inc. (NASDAQ:CBRS) operates as an artificial intelligence infrastructure company, designing and manufacturing an AI compute platform made up of proprietary systems and software for deployment in data centers up to supercomputer scale.
